Asparginase For Injection

Powder Injections

Powder Injections

Customers can avail from us an extensive array of Powder Injections which is prepared from high-grade components as per the set industry norms.



Each tablet contains Levothyroxine (as LEVOTHYROXINE sodium BP) 25/50/100/200 mg

Pharmacological classification & ATC Classification:
H03AA01 - levothyroxine sodium ; Belongs to the class of thyroid hormones.

Levothyroxine sodium increases the basal metabolic rate (BMR) of carbohydrates, fats and proteins. It is also involved in the regulation and differentiation of cell growth. These effects are mediated at the cellular level by the thyroxine metabolite, tri-iodothyronine.

Onset: Oral: 3-5 days; IV: 6-8 hr.

Absorption: Variable but adequate from the GI tract (oral); increased in fasting state.

Distribution: Crosses the placenta; enters breast milk. Protein-binding: Extensive to thyroxine-binding globulin.

Metabolism: Hepatic and renal; converted to liothyronine and inactive reverse triiodothyronine; undergoes enterohepatic recirculation.

Excretion: Via feces. Half-life: 6-7 days (euthyroid); prolonged in hypothyroidism and reduced in hyperthyroidism.

Levothyroxine is indicated in:

Asparginase For Injection

Asparginase For Injection

We are leading manufacturer and exporter of Asparaginase For Injection and our product is made up of good quality.


Each vial contains Asparginase 5000 IU or 10000 IU

Pharmacological classification & ATC Classification:
L01XX02 - asparaginase; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.

Asparaginase interferes with malignant cell growth by breaking down asparagine to aspartic acid and ammonia as leukemic cells are unable to synthesize asparagine and depend on the exogenous source of asparagine for survival. It acts on the G1 phase of the cell cycle.
Distribution: Distributed at lymph; does not penetrate the CSF.
Excretion: Urine (small amounts). Elimination half-life: 8-30 hr (IV); 49 hr (IM).

Asparaginase indicated in Induction of remission in acute lymphoblastic leukemia

Dosage & administration:
Induction of remission in acute lymphoblastic leukemia
Adult: 1000 units/kg/day via IV injection for 10 days after treatment with vincristine and prednisone or. Alternatively, 6000 units/m2 via IM injection, given every 3rd days for 9 doses during treatment with vincristine and prednisone or. As monotherapy: 200 units/kg/day via IV and for 28 days. IV injection to be given over at least 30 min in a running infusion of normal saline or glucose 5%. For IM admin, no more than 2 ml of a solution in normal saline should be injected at a single site.
Child: As monotherapy: 200 units/kg/day via IV injection for 28 days, to be given over at least 30 min in a running infusion of normal saline or glucose 5%.

Special Populations: NOTE: When administered IV, the drug should be given over 30 min along with NS or 5% dextrose.

Incompatibility: Incompatible with rubber and should not be mixed with other drugs.

Pancreatitis, hypersensitivity. Pregnancy.

Should be used after skin testing, in a hospital setting. Liver disease, frequently blood count monitoring. Lactation.

Side Effects:
Chills, pyrexia, liver disorders. Hyperammonaemia, a decrease of fibrinogen and clotting factors, alteration in blood lipids and cholesterol, hypoalbuminemia, uremia, renal failure (occasional). Hyperglycemia. Nausea, vomiting, anorexia, weight loss. CNS disturbances including depression, coma, hallucinations, Parkinson-like syndrome. Marked leucopenia, transient bone-marrow depression.
Potentially Fatal: Acute anaphylaxis; fatal hyperthermia; pancreatitis; ketoacidosis.

Drug Interactions:
The activity of methotrexate may be reduced if L-asparaginase is given beforehand.
Potentially Fatal: IV admin of asparaginase may increase vincristine neurotoxicity.

Pregnancy & Lactation:
Category C: Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.

Parenteral: Refrigerate at 2-8°C.

Packing presentations:
(Also can be packed according to customer’s requirement)
Vials containing lyophilized powder Each vial contains Asparaginase 5000 IU/ 10000 IU
Provide Us More Details
Purpose of Requirement:

Reselling End Use Raw Material


Looking for Asparginase For Injection ?


    We will contact you soon !

    Ganesh Iyer


    Cygnus Healthcare Specialities Private Limited, Mumbai

    Thane West, Thane, Maharashtra, India

    More Categories

    View All Categories »
    Send SMS
    Get Callback